Bio-Engine is a biotech startup that was founded in 2014. The company specializes in developing advanced high-density serum-free suspension culture methods for animal cells. Its key offerings include HEK293 and PK15 cell serum-free media, which are designed for applications in antibodies, recombinant proteins, human and animal virus vaccines, and cell therapy. The startup operates in the biopharma, biotechnology, and manufacturing industries. In its latest funding round in May 15, 2023, Bio-Engine secured a significant investment of CNY300.00M in a Series C - Bio investment. The investment was made by a consortium of prominent investors including Qingsong Fund, Legend Capital, Riverhead Capital Investment Management, NRL Capital, Yipu Capital, Jianfa Xinxing Investment, Huimei Capital, and Ningbo Leo Capital. Bio-Engine's successful fundraising efforts and its focus on cutting-edge biotech solutions indicate the company's potential for significant growth and impact within the industry. Its innovative approach to cell culture and strategic partnerships with major investors position the company as a key player in the biotech and manufacturing sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C - Bio | CNY300.00M | 9 |
|
15 May 2023 |
| Series B - Bio | Unknown | 1 |
|
27 Aug 2019 |
| Series A - Bio | Unknown | - | 01 Jun 2018 | |
| Series A - Bio | Unknown | - | 01 Mar 2016 |
No recent news or press coverage available for Bio-Engine.
We care about your data, and we'd love to use cookies make your experience better.